Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy.

Trial Profile

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy.

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perhexiline (Primary)
  • Indications Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms HYPER

Most Recent Events

  • 03 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
  • 19 Jul 2012 United Kingdom Clinical Research Network reports accrual to date changed from 54% to 56%.
  • 11 Aug 2011 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top